JP4889922B2 - 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 - Google Patents
少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 Download PDFInfo
- Publication number
- JP4889922B2 JP4889922B2 JP2003556050A JP2003556050A JP4889922B2 JP 4889922 B2 JP4889922 B2 JP 4889922B2 JP 2003556050 A JP2003556050 A JP 2003556050A JP 2003556050 A JP2003556050 A JP 2003556050A JP 4889922 B2 JP4889922 B2 JP 4889922B2
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- benzoyl peroxide
- composition
- water
- penetration enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 120
- 239000004342 Benzoyl peroxide Substances 0.000 title claims description 69
- 235000019400 benzoyl peroxide Nutrition 0.000 title claims description 69
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 title claims description 68
- 150000004492 retinoid derivatives Chemical class 0.000 title description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 206010000496 acne Diseases 0.000 claims description 21
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 20
- 239000003349 gelling agent Substances 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000008346 aqueous phase Substances 0.000 claims description 14
- 239000003961 penetration enhancing agent Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 238000009736 wetting Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 10
- 229960002916 adapalene Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 230000008030 elimination Effects 0.000 claims description 5
- 238000003379 elimination reaction Methods 0.000 claims description 5
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 4
- 229920002507 Poloxamer 124 Polymers 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 230000009931 harmful effect Effects 0.000 claims description 4
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940093448 poloxamer 124 Drugs 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- LPXFITACVAQQAL-UHFFFAOYSA-M sodium;prop-2-enoylazanide Chemical group [Na+].[NH-]C(=O)C=C LPXFITACVAQQAL-UHFFFAOYSA-M 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 230000003676 hair loss Effects 0.000 claims description 3
- 208000029443 keratinization disease Diseases 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940104261 taurate Drugs 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 239000012072 active phase Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 15
- 239000002537 cosmetic Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- -1 mizolastine) Chemical compound 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- 229920002509 Poloxamer 182 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940009868 aluminum magnesium silicate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 235000020682 bottled natural mineral water Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940093426 poloxamer 182 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0116747 | 2001-12-21 | ||
| FR0116747A FR2833841B1 (fr) | 2001-12-21 | 2001-12-21 | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
| PCT/FR2002/004233 WO2003055472A1 (fr) | 2001-12-21 | 2002-12-09 | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264093A Division JP5478468B2 (ja) | 2001-12-21 | 2010-11-26 | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005513146A JP2005513146A (ja) | 2005-05-12 |
| JP4889922B2 true JP4889922B2 (ja) | 2012-03-07 |
Family
ID=8870899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556050A Expired - Lifetime JP4889922B2 (ja) | 2001-12-21 | 2002-12-09 | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
| JP2010264093A Expired - Lifetime JP5478468B2 (ja) | 2001-12-21 | 2010-11-26 | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010264093A Expired - Lifetime JP5478468B2 (ja) | 2001-12-21 | 2010-11-26 | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1458369B1 (Direct) |
| JP (2) | JP4889922B2 (Direct) |
| KR (1) | KR101014586B1 (Direct) |
| CN (1) | CN1329025C (Direct) |
| AR (1) | AR038026A1 (Direct) |
| AT (1) | ATE347354T1 (Direct) |
| AU (2) | AU2002364437B2 (Direct) |
| BR (1) | BRPI0214264B8 (Direct) |
| CA (1) | CA2466321C (Direct) |
| CY (1) | CY1107583T1 (Direct) |
| DE (2) | DE122008000041I1 (Direct) |
| DK (1) | DK1458369T3 (Direct) |
| ES (1) | ES2275948T3 (Direct) |
| FR (2) | FR2833841B1 (Direct) |
| HU (1) | HU230439B1 (Direct) |
| MX (1) | MXPA04005918A (Direct) |
| PL (1) | PL220838B1 (Direct) |
| PT (1) | PT1458369E (Direct) |
| RU (1) | RU2320327C2 (Direct) |
| SI (1) | SI1458369T1 (Direct) |
| WO (1) | WO2003055472A1 (Direct) |
| ZA (1) | ZA200403759B (Direct) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011037904A (ja) * | 2001-12-21 | 2011-02-24 | Galderma Research & Development | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
| US8936800B2 (en) | 2001-12-21 | 2015-01-20 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1813312A3 (en) * | 2002-09-05 | 2010-03-24 | Galderma Research & Development | Depigmenting composition for the skin comprising adapalene and at least one depigmenting agent |
| US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
| ES2344214T3 (es) * | 2004-11-09 | 2010-08-20 | Imaginative Research Associates, Inc. | Soluciones de retinoides y formulaciones preparadas a partir de estas. |
| CN101277757B (zh) | 2005-08-02 | 2011-11-30 | 索尔-格尔科技有限公司 | 非水溶性成分的金属氧化物涂布 |
| FR2889662B1 (fr) * | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007052157A2 (en) * | 2005-09-02 | 2007-05-10 | Galderma Research & Development | Depigmenting composition for the skin, comprising adapalene, at least one depigmenting agent and at least one anti-inflammatory agent |
| FR2890314B1 (fr) * | 2005-09-02 | 2009-03-20 | Galderma Res & Dev | Compositiondepigmentante de la peau comprenant de l'adapalene au moins un agent depigmentant et au moins un agent anti-inflammatoire |
| KR101368107B1 (ko) | 2006-03-31 | 2014-03-14 | 스티펠 리서치 오스트레일리아 피티와이 리미티드 | 발포성 현탁겔 |
| FR2901139B1 (fr) * | 2006-05-17 | 2009-03-20 | Galderma Res & Dev S N C Snc | Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations |
| FR2903603B1 (fr) * | 2006-07-13 | 2009-03-20 | Galderma Res & Dev S N C Snc | Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne |
| WO2008006848A1 (en) * | 2006-07-13 | 2008-01-17 | Galderma Research & Development | Composition comprising a retinoid and benzoyl peroxide |
| FR2903604B1 (fr) * | 2006-07-13 | 2008-09-05 | Galderma Res & Dev S N C Snc | Composition comprenant un retinoide et du peroxyde de benzoyle |
| US8080537B2 (en) | 2006-07-13 | 2011-12-20 | Galderma Research & Development | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
| FR2909000B1 (fr) * | 2006-11-28 | 2009-02-06 | Galderma Res & Dev S N C Snc | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. |
| FR2910321B1 (fr) * | 2006-12-21 | 2009-07-10 | Galderma Res & Dev S N C Snc | Gel creme comprenant au moins un retinoide et du peroxyde de benzole |
| FR2910320B1 (fr) * | 2006-12-21 | 2009-02-13 | Galderma Res & Dev S N C Snc | Emulsion comprenant au moins un retinoide et du peroxyde de benzole |
| DK2114392T3 (en) * | 2007-01-30 | 2015-09-07 | Galderma Res & Dev | Applied adapalene and benzoyl peroxide FOR LONG-TERM TREATMENT OF ACNE VULGARIS |
| WO2008093346A2 (en) | 2007-02-01 | 2008-08-07 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising a peroxide and retinoid |
| EA018275B1 (ru) | 2007-02-01 | 2013-06-28 | Сол-Джел Текнолоджиз Лтд. | Способ получения частиц, содержащих покрытие из оксида металла, и частицы с покрытием из оксида металла |
| EP1967180A1 (de) * | 2007-03-06 | 2008-09-10 | Almirall Hermal GmbH | Topische Zusammensetzung enthaltend einen Retinoid-Rezeptor-Agonist |
| FR2916975B1 (fr) * | 2007-06-11 | 2009-09-04 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations |
| FR2916966B1 (fr) * | 2007-06-11 | 2011-01-14 | Galderma Res & Dev | Compositions comprenant au moins un compose retinoide, un compose anti-irritant et du peroxyde de benzoyle, et leurs utilisations |
| EP2065032A1 (en) * | 2007-11-27 | 2009-06-03 | Galderma Research & Development | A method for producing adapalene gels |
| AU2008337395B2 (en) * | 2007-11-30 | 2014-09-11 | Galderma Research & Development | Compositions containing at least one naphthoic acid derivative, benzoyl peroxide and at least one film-forming agent |
| MX2010013152A (es) * | 2008-06-05 | 2011-05-02 | Dow Pharmaceutical Sciences | Formulaciones farmaceuticas topicas que contienen una baja concentracion de peroxido de benzoilo en suspension en agua y un solvente organico miscibe en agua. |
| AU2009311239B2 (en) | 2008-11-07 | 2012-11-15 | Klox Technologies Inc. | Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin |
| CN102686208A (zh) | 2009-10-07 | 2012-09-19 | 塔格拉生物科技有限公司 | 包含过氧化苯甲酰的微胶囊和包含所述微胶囊的局部用组合物 |
| JP5784619B2 (ja) * | 2009-10-21 | 2015-09-24 | ドウ ファーマシューティカル サイエンシーズ、インク． | 過酸化ベンゾイルを含む粉末を湿潤させるための方法 |
| WO2011098391A1 (en) | 2010-02-09 | 2011-08-18 | Galderma Research & Development | A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non- caucasian population with decrease of post- inflammatory hyperpigmentation |
| FR2969491B1 (fr) * | 2010-12-23 | 2013-07-12 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo |
| FR2969492B1 (fr) * | 2010-12-23 | 2013-07-05 | Galderma Res & Dev | Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene |
| US8563535B2 (en) | 2011-03-29 | 2013-10-22 | Kamal Mehta | Combination composition comprising benzoyl peroxide and adapalene |
| JP2015517559A (ja) | 2012-05-25 | 2015-06-22 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 思春期前中程度の尋常性ざ瘡の治療 |
| HRP20182062T1 (hr) * | 2012-11-13 | 2019-02-08 | Galderma S.A. | Gelni pripravak za ispiranje koji sadrži bpo |
| US9687465B2 (en) | 2012-11-27 | 2017-06-27 | Sol-Gel Technologies Ltd. | Compositions for the treatment of rosacea |
| US20160310512A1 (en) | 2013-12-19 | 2016-10-27 | Galderma Research & Development | Therapy regimen for treating severe acne related diseases |
| AU2015239688B2 (en) | 2014-04-01 | 2020-06-25 | Galderma Research & Development | Combination of adapalene and benzoyl peroxide for treating acne scars |
| ES2828699T3 (es) | 2014-07-25 | 2021-05-27 | Galderma Res & Dev | Combinación de adapaleno y peróxido de benzoilo para el tratamiento del acné grave |
| CA2996022C (en) * | 2015-08-20 | 2021-01-05 | Sol-Gel Technologies Ltd. | Compositions for topical application comprising benzoyl peroxide and adapalene |
| WO2018080284A1 (ko) * | 2016-10-31 | 2018-05-03 | (주)동구바이오제약 | 여드름 치료용 약물의 생체이용률을 증진시키는 약학적 조성물 |
| CN106729722B (zh) * | 2016-11-21 | 2020-05-12 | 成都山信药业有限公司 | 一种制备稳定复方制剂的方法及复方制剂 |
| ES3040940T3 (en) | 2017-07-12 | 2025-11-05 | Sol Gel Tech Ltd | Compositions comprising encapsulated tretinoin |
| BR112021019904A2 (pt) * | 2019-04-04 | 2021-12-07 | Galderma Holding SA | Composições de isopropillcarbonato benzoil peróxido e métodos de uso |
| WO2023112664A1 (ja) * | 2021-12-14 | 2023-06-22 | ロート製薬株式会社 | 過酸化ベンゾイルを含有する医薬外用組成物 |
| WO2023177625A1 (en) * | 2022-03-14 | 2023-09-21 | Blue Hill Technologies Llc | Shelf-stable formulations of benzoyl peroxide and methods of producing same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2378523A1 (fr) * | 1977-01-26 | 1978-08-25 | Grupper Charles | Medicament pour le traitement de l'acne |
| US4189501A (en) * | 1977-10-07 | 1980-02-19 | A. H. C. Pharmacal, Inc. | Composition and method for the treatment of acne |
| LU85849A1 (fr) * | 1985-04-11 | 1986-11-05 | Cird | Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| FR2628319B1 (fr) * | 1988-03-09 | 1990-12-07 | Oreal | Compositions pharmaceutiques et cosmetiques a base de peroxyde de benzoyle et de sels d'ammonium quaternaires |
| AU675210B2 (en) * | 1991-10-16 | 1997-01-30 | Richardson-Vicks Inc. | Low pH aqueous cosmetic gel containing non-ionic polyacrylamide derivatives |
| US5470884A (en) * | 1994-05-19 | 1995-11-28 | Procter & Gamble | Anti-acne compositions |
| FR2785284B1 (fr) * | 1998-11-02 | 2000-12-01 | Galderma Res & Dev | Analogues de la vitamine d |
| FR2787322B1 (fr) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
| DE50014447D1 (de) * | 1999-12-20 | 2007-08-09 | Henkel Kgaa | Tablettierung verdickender systeme |
| FR2833841B1 (fr) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | Gel comprenant au moins un retinoide et du peroxyde de benzoyle |
-
2001
- 2001-12-21 FR FR0116747A patent/FR2833841B1/fr not_active Expired - Fee Related
-
2002
- 2002-12-09 RU RU2004122429/15A patent/RU2320327C2/ru active
- 2002-12-09 CN CNB028258460A patent/CN1329025C/zh not_active Expired - Lifetime
- 2002-12-09 JP JP2003556050A patent/JP4889922B2/ja not_active Expired - Lifetime
- 2002-12-09 EP EP02799797A patent/EP1458369B1/fr not_active Expired - Lifetime
- 2002-12-09 SI SI200230454T patent/SI1458369T1/sl unknown
- 2002-12-09 MX MXPA04005918A patent/MXPA04005918A/es active IP Right Grant
- 2002-12-09 DE DE122008000041C patent/DE122008000041I1/de active Pending
- 2002-12-09 PL PL372270A patent/PL220838B1/pl unknown
- 2002-12-09 DK DK02799797T patent/DK1458369T3/da active
- 2002-12-09 AU AU2002364437A patent/AU2002364437B2/en not_active Expired
- 2002-12-09 CA CA2466321A patent/CA2466321C/fr not_active Expired - Fee Related
- 2002-12-09 AT AT02799797T patent/ATE347354T1/de active
- 2002-12-09 BR BRPI0214264A patent/BRPI0214264B8/pt not_active IP Right Cessation
- 2002-12-09 ES ES02799797T patent/ES2275948T3/es not_active Expired - Lifetime
- 2002-12-09 DE DE60216634T patent/DE60216634T2/de not_active Expired - Lifetime
- 2002-12-09 KR KR1020047008461A patent/KR101014586B1/ko not_active Expired - Lifetime
- 2002-12-09 HU HU0500006A patent/HU230439B1/hu unknown
- 2002-12-09 PT PT02799797T patent/PT1458369E/pt unknown
- 2002-12-09 WO PCT/FR2002/004233 patent/WO2003055472A1/fr not_active Ceased
- 2002-12-18 AR ARP020104930A patent/AR038026A1/es not_active Application Discontinuation
-
2004
- 2004-05-17 ZA ZA2004/03759A patent/ZA200403759B/en unknown
-
2007
- 2007-01-29 CY CY20071100120T patent/CY1107583T1/el unknown
-
2008
- 2008-06-05 FR FR08C0024C patent/FR08C0024I2/fr active Active
- 2008-11-21 AU AU2008246274A patent/AU2008246274B2/en not_active Expired
-
2010
- 2010-11-26 JP JP2010264093A patent/JP5478468B2/ja not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011037904A (ja) * | 2001-12-21 | 2011-02-24 | Galderma Research & Development | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 |
| US8936800B2 (en) | 2001-12-21 | 2015-01-20 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
| US9814690B2 (en) | 2001-12-21 | 2017-11-14 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4889922B2 (ja) | 少なくとも一つのレチノイド及び過酸化ベンゾイルを含むゲル組成物 | |
| US8936800B2 (en) | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | |
| JP5666654B2 (ja) | レチノイドと過酸化ベンゾイルとを含む組成物 | |
| KR101500767B1 (ko) | 하나 이상의 레티노이드 및 벤조일 퍼옥시드를 포함하는 크림 젤 | |
| KR101455038B1 (ko) | 하나 이상의 레티노이드 및 벤조일 퍼옥시드를 포함하는 유화액 | |
| PT1464321E (pt) | Composição de coloração para matérias ceratínicas humanas compreendendo um corante fluorescente e um silicone aminado, processo e utilização | |
| BRPI0713221B1 (pt) | composição, uso de uma composição e uso cosmético de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090916 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091211 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101126 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110530 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110713 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111115 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4889922 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141222 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |